TELA Bio (TELA) Liabilities and Shareholders Equity (2018 - 2026)

TELA Bio has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $59.7 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 11.55% year-over-year to $59.7 million in Q2 2026; TTM through Jun 2026 was $272.6 million, a 4.13% decrease from a year earlier, with the FY2025 full-year figure at $81.4 million, down 5.95% from the prior year.
• Liabilities and Shareholders Equity was $59.7 million for Q2 2026 at TELA Bio, down from $69.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $94.4 million in Q2 2023, with the low at $51.3 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $70.1 million, with a median of $68.9 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity jumped 83.87% in 2023, then sank 39.28% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $67.9 million in 2022, then rose by 15.02% to $78.0 million in 2023, then advanced by 10.92% to $86.6 million in 2024, then slipped by 5.95% to $81.4 million in 2025, then decreased by 26.63% to $59.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $59.7 million (Q2 2026), $69.9 million (Q1 2026), and $81.4 million (Q4 2025), per Business Quant data.